Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Enterprise Value (2016 - 2025)

Adma Biologics' Enterprise Value history spans 14 years, with the latest figure at -$87.6 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 15.04% year-over-year to -$87.6 million; the TTM value through Dec 2025 reached -$87.6 million, up 15.04%, while the annual FY2025 figure was -$87.6 million, 15.04% up from the prior year.
  • Enterprise Value reached -$87.6 million in Q4 2025 per ADMA's latest filing, down from -$61.4 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$34.4 million in Q3 2021 to a low of -$103.1 million in Q4 2024.
  • Average Enterprise Value over 5 years is -$66.2 million, with a median of -$65.9 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: soared 42.34% in 2021, then tumbled 112.57% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$51.1 million in 2021, then tumbled by 69.36% to -$86.5 million in 2022, then surged by 40.65% to -$51.4 million in 2023, then tumbled by 100.86% to -$103.1 million in 2024, then grew by 15.04% to -$87.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Enterprise Value are -$87.6 million (Q4 2025), -$61.4 million (Q3 2025), and -$90.3 million (Q2 2025).